Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | MDM4 | O15151 | 1/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.41 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.41 |
| ▸ | GFPT1 | Q06210 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL196572 | 1.00 | MAPT (0.47) | MAPTLMNAMDM4MDM2HCAR2 | |
| SCHEMBL2118341 | 0.81 | MAPT (0.48) | MAPTLMNAMDM4MDM2HCAR2 | |
| SCHEMBL2118339 | 0.81 | MAPT (0.48) | MAPTLMNAMDM4MDM2HCAR2 | |
| SCHEMBL18288665 | 0.78 | LMNA (0.60) | MAPTLMNAMDM4MDM2ALDH1A1 | |
| SCHEMBL18202830 | 0.78 | HCAR2 (0.41) | HCAR2KEAP1NFE2L2SMN1; SMN2GFPT1 | |
| SCHEMBL17688554 | 0.77 | HCAR2 (0.52) | MAPTLMNAHCAR2KEAP1NFE2L2 | |
| SCHEMBL17688555 | 0.77 | HCAR2 (0.52) | MAPTLMNAHCAR2KEAP1NFE2L2 | |
| SCHEMBL3397754 | 0.76 | SMN1; SMN2 (0.51) | MAPTALDH1A1SMN1; SMN2KDM4EHSD17B10 | |
| SCHEMBL2294082 | 0.76 | SMN1; SMN2 (0.51) | MAPTALDH1A1SMN1; SMN2KDM4EHSD17B10 | |
| SCHEMBL2294079 | 0.76 | SMN1; SMN2 (0.51) | MAPTALDH1A1SMN1; SMN2KDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785443-B2 | Methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof | XENOPORT, INC. (US) | 2014-07-22 | — | — | US | claimed |
| US-20120095003-A1 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | XENOPORT, INC. (US) | 2012-04-19 | — | — | US | claimed |
| US-8148414-B2 | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use | XENOPORT, INC. (US) | 2012-04-03 | — | — | US | claimed |
| JP-2012500285-A | — | — | 2012-01-05 | — | — | JP | claimed |
| EP-2334378-A2 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XenoPort, Inc. (US) | 2011-06-22 | — | — | EP | claimed |
| WO-2010022177-A2 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-02-25 | — | — | WO | claimed |
| US-20100048651-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-02-25 | — | — | US | claimed |
| US-20260007627-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | BIOGEN MA INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-20240240229-A1 | METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2024-07-18 | — | — | US | disclosed |
| EP-4215191-A1 | COMPOSITION COMPRISING A FUMARATE FOR USE IN A METHOD OF TREATING MULTIPLE SCLEROSIS | Biogen MA Inc. (US) | 2023-07-26 | — | — | EP | disclosed |
| EP-4215191-A1 | COMPOSITION COMPRISING A FUMARATE FOR USE IN A METHOD OF TREATING MULTIPLE SCLEROSIS | Biogen MA Inc. (US) | 2023-07-26 | — | — | EP | disclosed |
| CN-115531366-A | Method of treating multiple sclerosis | 渤健马萨诸塞州股份有限公司 | 2022-12-30 | — | — | CN | disclosed |
| CN-115501218-A | Methods of treating multiple sclerosis | 渤健马萨诸塞州股份有限公司 | 2022-12-23 | — | — | CN | disclosed |
| WO-2013119677-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE | BIOGEN IDEC MA INC. (US) | 2013-08-15 | — | — | WO | disclosed |
| US-20120157523-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120095003-A1 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | XENOPORT, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-8148414-B2 | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use | XENOPORT, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| EP-2334378-A2 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XenoPort, Inc. (US) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010022177-A2 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| US-20100048651-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157523-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, MGMT, BHMT2 | MAPT 1222/4885LMNA 4568/4885MDM4 1205/4885 |
| US-20120095003-A1 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | FH, MGMT, BHMT2 | MAPT 1398/4885LMNA 4576/4885MDM4 1102/4885 |
| US-20260007627-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | FH, SLC6A6, SLC6A13 | MAPT 25/4885LMNA 1608/4885MDM4 842/4885 |
| US-20240240229-A1 | METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS | GSTM1, GSTM2, GSTA1 | MAPT 2243/4885LMNA 4660/4885MDM4 596/4885 |
| US-20100048651-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, MGMT, BHMT2 | MAPT 1222/4885LMNA 4568/4885MDM4 1205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.